Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Labeling Reg Deferral For Convenience Size OTCs To Be Issued By FDA

Executive Summary

FDA will publish a notice to "delay the compliance date of the current Drug Facts rules with respect to 'convenience-size' drug packages" in an upcoming issue of the Federal Register, the agency says in a recent letter to Lil' Drug Store Products
Advertisement

Related Content

“Convenience-Size” OTCs Inner Package Labeling Limits Supported
“Convenience-Size” OTCs Inner Package Labeling Limits Supported
“Drug Facts” Consumer Understanding Dependant On Education – FDA
“Drug Facts” Consumer Understanding Dependant On Education – FDA
OTC Labeling Compliance Date Delayed For “Convenience-Size” Items
OTC Labeling Compliance Date Delayed For “Convenience-Size” Items
Block Drug OTC Small Packaging Denial Mishandled By FDA, CHPA Says
OTC Small Package Exemptions To Be Handled Via Monograph Process - FDA
OTC Small Package Exemptions To Be Handled Via Monograph Process - FDA
Advertisement
UsernamePublicRestriction

Register

RS010009

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel